Avodart prevents the conversion of testosterone to dihydrotestosterone (DHT) in the body.
GSK said that it will withdraw applications from regulatory review where procedures are ongoing and, in the limited number of countries where dutasteride is already indicated for use in prostate cancer risk reduction.